MARKET

HZNP

HZNP

Horizon Therapeutics Pub L
NASDAQ
61.89
-0.80
-1.28%
After Hours: 61.89 0 0.00% 16:22 09/30 EDT
OPEN
63.05
PREV CLOSE
62.69
HIGH
64.16
LOW
61.85
VOLUME
2.04M
TURNOVER
0
52 WEEK HIGH
120.54
52 WEEK LOW
57.84
MARKET CAP
14.26B
P/E (TTM)
19.12
1D
5D
1M
3M
1Y
5Y
Horizon Therapeutics Announced New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 (IGF-1) in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting (AAO 2022), Sept.
Benzinga · 14h ago
Horizon Therapeutics plc Completes Enrollment For Phase 4 Trial Of TEPEZZA In Adults With Chronic/Low Clinical Activity Score Thyroid Eye Disease
Horizon Therapeutics plc (NASDAQ:HZNP) announced that it has completed enrollment of its Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low
Benzinga · 4d ago
Horizon Therapeutics Completes Enrollment for Phase 4 Trial of Tepezza in Thyroid Eye Disease
Horizon Therapeutics Completes Enrollment for Phase 4 Trial of Tepezza in Thyroid Eye Disease
MT Newswires · 4d ago
Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Horizon Therapeutics (NASDAQ:HZNP) has had a rough three months with its share price down 26%. But if you pay close...
Simply Wall St. · 09/26 10:59
Horizon pays HemoShear milestone payment under pact to develop gout therapies
Horizon Therapeutics (NASDAQ:HZNP) <a...
Seekingalpha · 09/21 12:04
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
DUBLIN, September 21, 2022--Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce the winning solution of this year’s Horizon Prize: Patient-Driven Data Platform for Rare ...
Business Wire · 09/21 12:04
Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
DUBLIN, September 19, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for a series of data presentations on its marketed and pipeline medicines, with a focus on continued efforts to advance the understanding and care of uncontrolled gou...
Business Wire · 09/19 12:00
Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
DUBLIN, September 16, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the University of Notre Dame’s Patient Advocacy Initiative in the College of Science. The gift will help advance Notre D...
Business Wire · 09/16 13:00
More
About HZNP
Horizon Therapeutics plc is a global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. The Company operates through two segments: orphan segment and the inflammation segment. The orphan segment includes medicines, such as TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase injection), RAVICTI (glycerol phenylbutyrate), PROCYSBI (cysteamine bitartrate), UPLIZNA (inebilizumab-cdon) injection, ACTIMMUNE (interferon gamma-1b) injection, BUPHENYL (sodium phenylbutyrate) tablets and powder, and QUINSAIR (levofloxacin) solution. The inflammation segment includes medicines, such as PENNSAID (diclofenac sodium topical solution), RAYOS (prednisone), VIMOVO (naproxen), and DUEXIS (ibuprofen).

Webull offers kinds of Horizon Therapeutics PLC stock information, including NASDAQ:HZNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HZNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HZNP stock methods without spending real money on the virtual paper trading platform.